Search Results - "INTERLEUKIN-2 THERAPY"

Directed disruption of IL2 aggregation and receptor binding sites produces designer biologics with enhanced specificity and improved production capacity

Authors: Amy Dashwood Ntombizodwa Makuyana Rob van der Kant et al.

Contributors: Amy Dashwood Ntombizodwa Makuyana Rob van der Kant et al.

Source: Comput Struct Biotechnol J
Computational and Structural Biotechnology Journal, Vol 27, Iss, Pp 1112-1123 (2025)

Subject Terms: Biochemistry & Molecular Biology, 3101 Biochemistry and cell biology, Science & Technology, COMPLEX, PREDICTION, 0103 Numerical and Computational Mathematics, 4601 Applied computing, SEQUENCE, HUMAN IL-2, Biotechnology & Applied Microbiology, ALPHA-RECEPTOR, T-CELLS, Interleukin-2, INTERLEUKIN-2 THERAPY, Protein engineering, PROTEIN AGGREGATION, Life Sciences & Biomedicine, Cytokine, IN-VIVO, TP248.13-248.65, 0802 Computation Theory and Mathematics, Biotechnology, Research Article

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40190571
https://doaj.org/article/bbf5a2197aa04d7885455a6e9ab2ddf3

Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation

Authors: Yusuke Meguri Takeru Asano Takanori Yoshioka et al.

Source: Frontiers in Immunology, Vol 13 (2022)

Subject Terms: regulatory T cell, low-dose interleukin-2 therapy, graft-versus-host disease, graft-versus-leukemia effect, transplantation tolerance, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2022.891925/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/42a265b21bcb45fca535e41a4d4f72df

Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter

Authors: Eskandari, Siawosh K. Sulkaj, Ina Melo, Mariane B. et al.

Source: Eskandari, S K, Sulkaj, I, Melo, M B, Li, N, Allos, H, Alhaddad, J B, Kollar, B, Borges, T J, Eskandari, A S, Zinter, M A, Cai, S, Assaker, J P, Choi, J Y, Al Dulaijan, B S, Mansouri, A, Haik, Y, Tannous, B A, van Son, W J, Leuvenink, H G D, Pomahac, B, Riella, L, Tang, L, Seelen, M A J, Irvine, D J & Azzi, J R 2020, 'Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter', Science Translational Medicine, vol. 12, no. 569, 4744, pp. 1-16. https://doi.org/10.1126/scitranslmed.aaw4744

Subject Terms: DOSE INTERLEUKIN-2 THERAPY, ALLOGRAFT-REJECTION, MESSENGER-RNA, IN-VITRO, ACTIVATION, MEMORY, FOXP3, AUTOIMMUNE, TOLERANCE, TRANSPLANTATION

File Description: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/wos/000590468700004; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/a66683b5-ceaf-4801-ac08-3c86f07c382a; info:eu-repo/semantics/altIdentifier/pissn/1946-6234

Availability: https://hdl.handle.net/11370/a66683b5-ceaf-4801-ac08-3c86f07c382a
https://research.rug.nl/en/publications/a66683b5-ceaf-4801-ac08-3c86f07c382a
https://doi.org/10.1126/scitranslmed.aaw4744
https://pure.rug.nl/ws/files/156482309/Regulatory_T_cells_engineered_with_TCR_signaling_responsive_IL_2_nanogels_suppress_alloimmunity_in_sites_of_antigen_encounter.pdf
https://www.scopus.com/pages/publications/85096082494

Multifarious immunotherapeutic approaches to cure HIV-1 infection

Authors: Imami, N Herasimtschuk, AA Medical Research Council (MRC) et al.

Contributors: Imami, N Herasimtschuk, AA Medical Research Council (MRC) et al.

Source: Hum Vaccin Immunother

Subject Terms: Adult, 0301 basic medicine, Immunology, antiretroviral therapy, retroviral persistence, HIV Infections, Young Adult, 03 medical and health sciences, LATENT RESERVOIR, 80 and over, Humans, functional cure, DOSE GROWTH-HORMONE, INTERLEUKIN-2 THERAPY, IN-VIVO, Aged, Aged, 80 and over, 0303 health sciences, Science & Technology, ACTIVE ANTIRETROVIRAL THERAPY, T-CELL RESPONSES, therapeutic vaccines, Middle Aged, DNA VACCINE, Combined Modality Therapy, Virus Latency, 3. Good health, Biotechnology & Applied Microbiology, Anti-Retroviral Agents, HIV-1-INFECTED INDIVIDUALS, T-cell responses, Commentary, HIV-1, IMMUNE RESTORATION, immunotherapy, Immunotherapy, Life Sciences & Biomedicine, CD4(+)

Access URL: https://www.tandfonline.com/doi/pdf/10.1080/21645515.2015.1021523?needAccess=true
https://pubmed.ncbi.nlm.nih.gov/26048144
http://europepmc.org/articles/PMC4635699
https://core.ac.uk/display/77009910
https://spiral.imperial.ac.uk/handle/10044/1/32979
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635699/
https://www.tandfonline.com/doi/full/10.1080/21645515.2015.1021523
https://www.tandfonline.com/doi/pdf/10.1080/21645515.2015.1021523
http://hdl.handle.net/10044/1/32979

Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection

Authors: Herasimtschuk, A Downey, J Nelson, M et al.

Contributors: Herasimtschuk, A Downey, J Nelson, M et al.

Source: Vaccine. 32:7005-7013

Subject Terms: CD4-Positive T-Lymphocytes, Male, 0301 basic medicine, Enzyme-Linked Immunospot Assay, HIV Antigens, HIV Infections, Research & Experimental Medicine, Lymphocyte Activation, 7. Clean energy, Proviruses, Vaccines, DNA, DOSE GROWTH-HORMONE, IN-VIVO, AIDS Vaccines, Vaccines, 0303 health sciences, ACTIVE ANTIRETROVIRAL THERAPY, Research & Experimental, 11 Medical And Health Sciences, Middle Aged, Flow Cytometry, Combined Modality Therapy, 3. Good health, Treatment Outcome, Medicine, Research & Experimental, Anti-Retroviral Agents, HIV-1-INFECTED INDIVIDUALS, Medicine, Cytokines, TRIAL, Life Sciences & Biomedicine, DNA vaccine, Adult, Immunology, Immunophenotyping, 03 medical and health sciences, Virology, Humans, INTERLEUKIN-2 THERAPY, COMBINATION, INTERRUPTION, Science & Technology, Perforin, IL-2, DNA, 06 Biological Sciences, DNA VACCINE, Growth Hormone, HIV-1, 07 Agricultural And Veterinary Sciences, Immune-based therapy

Access URL: https://pubmed.ncbi.nlm.nih.gov/25454870
http://www.sciencedirect.com/science/article/pii/S0264410X1401384X
https://www.cabdirect.org/cabdirect/abstract/20153008205
https://www.sciencedirect.com/science/article/pii/S0264410X1401384X
https://pubag.nal.usda.gov/catalog/5350234
https://pubmed.ncbi.nlm.nih.gov/25454870/
https://europepmc.org/article/MED/25454870
http://hdl.handle.net/10044/1/61508

Immunotherapy and biological modifiers for the treatment of malignant brain tumors

Authors: Marras, Carlo Mendola, Carmela Legnani, Federico Giuseppe et al.

Source: Current Opinion in Oncology. 15:204-208

Subject Terms: Male, Clinical Trials as Topic, central-nervous-system, messenger-RNA expression, neural stem-cells, glioma-cells, glioblastoma-multiforme, in-vivo, gene-transfer, interleukin-2 therapy, intracranial gliomas, immunogene therapy, Brain Neoplasms, Biopsy, Needle, Glioma, Prognosis, Sensitivity and Specificity, Survival Analysis, 3. Good health, Disease Models, Animal, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Histocompatibility, Animals, Cytokines, Humans, Female, Immunotherapy, Interferons, Telomerase, Biomarkers, Neoplasm Staging

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/12778012
https://jhu.pure.elsevier.com/en/publications/immunotherapy-and-biological-modifiers-for-the-treatment-of-malig-3
https://pubmed.ncbi.nlm.nih.gov/12778012/
https://moh-it.pure.elsevier.com/en/publications/immunotherapy-and-biological-modifiers-for-the-treatment-of-malig
http://www.ncbi.nlm.nih.gov/pubmed/12778012
https://journals.lww.com/00001622-200305000-00004

Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation

Authors: Meguri, Yusuke Asano, Takeru Yoshioka, Takanori et al.

Source: Frontiers In Immunology

Subject Terms: regulatory T cell, low-dose interleukin-2 therapy, graft-versus-host disease, graft-versus-leukemia effect, transplantation tolerance

Relation: info:pmid/35983059

Availability: https://ousar.lib.okayama-u.ac.jp/files/public/6/63866/20220905154301364635/fulltext.pdf
https://ousar.lib.okayama-u.ac.jp/63866

Interleukin-2 Therapie eines biochemischen Prostatakarzinomrezidivs nach radikaler Prostatektomie
Interleukin-2 therapy of a biochemical relapse after radical prostatektomy

Authors: Fiebiger, Katrin

Subject Terms: Interleukin-2- Therapie, biochemisches Rezidiv nach radikaler Prostatektomie, Interleukin-2- Therapy, biochemical relapse after radical prostatectomy, 610 Medizin, Gesundheit, 44.88 Urologie, Nephrologie, Prostatakrebs, ddc:610

Access URL: http://nbn-resolving.de/urn:nbn:de:gbv:18-23458
https://ediss.sub.uni-hamburg.de/handle/ediss/830

Cutaneous Metastases of Melanoma: New Treatment Options

Authors: Garbe, Claus Weide, Benjamin Pflugfelder, Annette et al.

Source: From Local Invasion to Metastatic Cancer ISBN: 9781603270861

Subject Terms: Immune-Response Modifier, Cooperative Oncology Group, Lentigo Maligna, High-Dose Interleukin-2, Recombinant Interleukin-2 Therapy, Phase-Ii Trial, Intralesional Therapy, 3. Good health, imiquimod, intratumoral treatment, cutaneous metastases, interleukin-2, Malignant-Melanoma, bleomycine, Melanoma, Topical Imiquimod, Long-Term Survival

Access URL: https://link.springer.com/content/pdf/10.1007%2F978-1-60327-087-8_49.pdf
https://rd.springer.com/chapter/10.1007/978-1-60327-087-8_49
https://espace.library.uq.edu.au/view/UQ:412345
https://link.springer.com/chapter/10.1007/978-1-60327-087-8_49/fulltext.html
https://core.ac.uk/display/83974777
https://link.springer.com/chapter/10.1007%2F978-1-60327-087-8_49

Technology evaluation: EMD-273063, EMD Lexigen

Authors: Niculescu-Duvaz, I Niculescu-Duvaz, Dan

Contributors: Niculescu-Duvaz, I Niculescu-Duvaz, Dan

Source: Current opinion in molecular therapeutics. 6(5)

Subject Terms: 0301 basic medicine, 0303 health sciences, Clinical Trials, Phase I as Topic, Drug Evaluation, Preclinical, Antibodies, Monoclonal, 3. Good health, Patents as Topic, 03 medical and health sciences, Neuroblastoma, Structure-Activity Relationship, Targeted interleukin-2 therapy antiganglioside gd2 antibody severe combined immunodeficiency dependent cellular cytotoxicity human neuroblastoma metastases high-dose interleukin-2 activated killer-cells phase-i trial fusion protein plus interleukin-2, Animals, Humans, Interleukin-2, Melanoma

Access URL: https://pubmed.ncbi.nlm.nih.gov/15537058

Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients

Authors: Rogiers, Aljosja van den Oord, Joost J. Garmyn, Maria et al.

Source: ISSN:1170-229X ; ISSN:1179-1969 ; Drugs & Aging, vol. 32 (10), (821-834.

Subject Terms: Science & Technology, Life Sciences & Biomedicine, Geriatrics & Gerontology, Pharmacology & Pharmacy, RECOMBINANT INTERLEUKIN-2 THERAPY, DISSEMINATED MALIGNANT-MELANOMA, PROGNOSTIC-FACTORS ANALYSIS, LYMPH-NODE POSITIVITY, CUTANEOUS MELANOMA, BRAF MUTATIONS, OPEN-LABEL, PHASE-III, SPONTANEOUS REGRESSION, INTERNATIONAL SOCIETY, Adult, Aged, Aging, Antineoplastic Agents, Humans, Immunotherapy, Lymphatic Metastasis, Melanoma, Middle Aged, Molecular Targeted Therapy, Skin Neoplasms, Cutaneous Malignant, 1115 Pharmacology and Pharmaceutical Sciences, Geriatrics, 3202 Clinical sciences, 3214 Pharmacology and pharmaceutical sciences

Relation: https://lirias.kuleuven.be/handle/123456789/544319; https://pubmed.ncbi.nlm.nih.gov/26442859

Availability: https://lirias.kuleuven.be/handle/123456789/544319
https://doi.org/10.1007/s40266-015-0304-7
https://pubmed.ncbi.nlm.nih.gov/26442859

Interleukin-2 Therapie eines biochemischen Prostatakarzinomrezidivs nach radikaler Prostatektomie ; Interleukin-2 therapy of a biochemical relapse after radical prostatektomy

Authors: Fiebiger, Katrin Huland, Edith (Prof. Dr. Dr.)

Contributors: Fiebiger, Katrin Huland, Edith (Prof. Dr. Dr.)

Subject Terms: Interleukin-2- Therapie, biochemisches Rezidiv nach radikaler Prostatektomie, Interleukin-2- Therapy, biochemical relapse after radical prostatectomy, 610 Medizin, Gesundheit, 44.88 Urologie, Nephrologie, Prostatakrebs, ddc:610

Availability: http://nbn-resolving.de/urn:nbn:de:gbv:18-23458
https://ediss.sub.uni-hamburg.de/handle/ediss/830

Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.

Authors: Asano, Takeru Yoshioka, Takanori Iwamoto, Miki et al.

Index Terms: regulatory T cell, low-dose interleukin-2 therapy, graft-versus-host disease, graft-versus-leukemia effect, transplantation tolerance, Journal Article., VoR.

URL: https://ousar.lib.okayama-u.ac.jp/63866
https://doi.org/10.3389/fimmu.2022.891925
https://ousar.lib.okayama-u.ac.jp/files/public/6/63866/20220905154301364635/fulltext.pdf
35983059